CT-868
Sources
registry, as of 2026-10-28Stale
https://clinicaltrials.gov/study/NCT06062069
A Study of CT-868 in Type 1 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE2. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 111. Conditions Overweight; Obese; Type 1 Diabetes Mellitus. This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabet Percentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20% Weight Loss at Week 16 Arm 1: All Placebo 2.0 Percentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20% Weight Loss at Week 16 Arm 2: CT-868 Titrated to 1.8 mg 6.0 Percentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20% Weight Loss at Week 16 Arm 3: CT-868 Titrated to 4.1 mg 15.0 Percentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20%
ClinicalTrials.gov NCT06062069 protocol and results modules
registry, as of 2026-02-05Stale
https://clinicaltrials.gov/study/NCT05110846
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE2. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 103. Conditions Obesity; Overweight; Type 2 Diabetes Mellitus. A study to assess the effect of CT-868 in lowering glycated hemoglobin A1c (HbA1c) in overweight and obese participants with inadequately controlled Type 2 diabetes mellitus (T2DM).
ClinicalTrials.gov NCT05110846 protocol and results modules
registry, as of 2024-12-27Stale
https://clinicaltrials.gov/study/NCT05794581
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes. Overall status COMPLETED. Phases PHASE1. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 32. Conditions Type 1 Diabetes. This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.
ClinicalTrials.gov NCT05794581 protocol and results modules
registry, as of 2025-03-28Stale
https://clinicaltrials.gov/study/NCT04973111
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose. Overall status COMPLETED. Phases PHASE1. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 32. Conditions Diabetes. A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
ClinicalTrials.gov NCT04973111 protocol and results modules